Utama › Limfoma Bukan Hodgkin › Oregon › Portland
Kajian klinikal Limfoma Bukan Hodgkin di Portland, OR
15 kajian untuk Limfoma Bukan Hodgkin sedang mencari peserta di lokasi dalam dan sekitar Portland (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Mengambil pesertaFasa 1/2
- Oregon Health and Sciences University, Portland
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Mengambil pesertaFasa 2
- Providence Health & Services, Portland
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Mengambil pesertaFasa 1
- Oregon Health & Science University (OHSU), Portland
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Mengambil pesertaFasa 2
- Research Site, Portland
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Mengambil pesertaFasa 2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Mengambil pesertaFasa 1/2
- Oregon Health & Science University, Portland
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Mengambil pesertaKajian pemerhatian
- Oregon Health and Science University Knight Cancer Institute, Portland
DALY II USA/ MB-CART2019.1 for DLBCL
Mengambil pesertaFasa 2
- Oregon Health and Science University Knight Cancer Institute, Portland
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Mengambil pesertaKajian pemerhatian
- Oregon Health & Science University/Doernbecher Children's Hospital, Portland
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Mengambil pesertaFasa 1/2
- Providence Neurological Specialties West, Portland
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Mengambil pesertaKajian pemerhatian
- Kaiser Permanente Northwest, Portland
Study of SGR-1505 in Mature B-Cell Neoplasms
Mengambil pesertaFasa 1
- Oregon Health and Science University - Knight Cancer Institute, Portland
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Mengambil pesertaKajian pemerhatian
- Local Institution - 0016, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Portland
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Mengambil pesertaFasa 1
- Oregon Health & Science University, Portland
Kajian Limfoma Bukan Hodgkin di bandar lain
- New York City, NY31 kajian
- Houston, TX31 kajian
- Boston, MA26 kajian
- Nashville, TN21 kajian
- Philadelphia, PA20 kajian
- Baldwin Park, CA19 kajian
- Washington, DC18 kajian
- Chicago, IL18 kajian
- Atlanta, GA18 kajian
- Milwaukee, WI18 kajian
- Columbus, OH18 kajian
- Dallas, TX17 kajian
Kajian lain di Portland
- Kanser Paru-paru Bukan Sel Kecil46 kajian
- Kanser (semua jenis)34 kajian
- Kanser Payudara33 kajian
- Kanser Prostat33 kajian
- Kanser Metastatik29 kajian
- Kanser Kolorektal28 kajian
- Kanser Ovari27 kajian
- Kanser Paru-paru26 kajian
- Leukemia Mieloid Akut25 kajian
- Kanser Endometrium24 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher19 kajian
- Kanser Pankreas19 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.